Education
About Us
Working with TipRanks
Follow Us
Upstream Bio, Inc. (UPB)
:UPB
UPB Analyst Ratings
Strong Buy
4 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
UPB Stock 12 Month Forecast
Average Price Target
$75.00
▲(334.28% Upside)
| Highest Price Target$75.00 | Average Price Target$75.00 | Lowest Price Target$75.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TD Cowen
―
Buy
―
Reiterated
09/04/25
J.P. Morgan
―
Buy
―
Reiterated
09/02/25
William Blair
―
Buy
―
Reiterated
09/02/25
Positive Buy Rating for Upstream Bio, Inc. Driven by Promising Clinical Trial Results for VerekitugWe believe this largely comes in line with data from Tezspire, which showed roughly a 1.7-point improvement over placebo at week 24 that further improved to 2.07 at week 52. A sensitivity analysis of the VIBRANT results using censoring of patients receiving rescue steroids would increase the treatment difference to 1.9 points on the primary endpoint of NPS, likely exceeding the results with Tezspire at a similar timepoint. As discussed in our recent KOL call on CRSwNP (see note here), there are nuances to measuring and analyzing change in NPS in clinical trials that make cross-trial comparisons difficult. While some investors had hoped for a NPS change of closer to 2.0, we do see the verekitug results as tracking right in line with the WAYPOINT data with Tezspire, as shown in exhibit 1.
Piper Sandler
$75
Buy
334.28%
Upside
Reiterated
08/26/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TD Cowen
―
Buy
―
Reiterated
09/04/25
J.P. Morgan
―
Buy
―
Reiterated
09/02/25
William Blair
―
Buy
―
Reiterated
09/02/25
Positive Buy Rating for Upstream Bio, Inc. Driven by Promising Clinical Trial Results for VerekitugWe believe this largely comes in line with data from Tezspire, which showed roughly a 1.7-point improvement over placebo at week 24 that further improved to 2.07 at week 52. A sensitivity analysis of the VIBRANT results using censoring of patients receiving rescue steroids would increase the treatment difference to 1.9 points on the primary endpoint of NPS, likely exceeding the results with Tezspire at a similar timepoint. As discussed in our recent KOL call on CRSwNP (see note here), there are nuances to measuring and analyzing change in NPS in clinical trials that make cross-trial comparisons difficult. While some investors had hoped for a NPS change of closer to 2.0, we do see the verekitug results as tracking right in line with the WAYPOINT data with Tezspire, as shown in exhibit 1.
Piper Sandler
$75
Buy
334.28%
Upside
Reiterated
08/26/25
Best Analysts Covering Upstream Bio, Inc.
1 Month
xxx
Success Rate
3/7 ratings generated profit
Average Return
+7.36%
reiterated a xxx
rating 18 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 42.86% of your transactions generating a profit, with an average return of +7.36% per trade.
3 Months
xxx
Success Rate
5/7 ratings generated profit
Average Return
+27.34%
reiterated a xxx
rating 18 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 71.43% of your transactions generating a profit, with an average return of +27.34% per trade.
1 Year
Success Rate
5/7 ratings generated profit
Average Return
+45.13%
reiterated a buy rating 18 days ago
Copying Matt Phipps's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +45.13% per trade.
2 Years
xxx
Success Rate
5/7 ratings generated profit
Average Return
+45.13%
reiterated a xxx
rating 18 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 71.43% of your transactions generating a profit, with an average return of +45.13% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
UPB Analyst Recommendation Trends
Rating
May 25
Jun 25
Jul 25
Aug 25
Sep 25
Strong Buy
2
1
4
4
4
Buy
5
5
8
9
9
Hold
1
4
8
8
6
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
8
10
20
21
19
Each month's total comprises the sum of three months' worth of ratings.
UPB Financial Forecast
UPB Stock Forecast FAQ
What is UPB’s average 12-month price target, according to analysts?
Based on analyst ratings, Upstream Bio, Inc.’s 12-month average price target is 75.00.
What is UPB’s upside potential, based on the analysts’ average price target?
Upstream Bio, Inc. has 334.28% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is UPB a Buy, Sell or Hold?
Upstream Bio, Inc. has a consensus rating of Strong Buy which is based on 4 buy ratings, 0 hold ratings and 0 sell ratings.
What is Upstream Bio, Inc.’s price target?
The average price target for Upstream Bio, Inc. is 75.00. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $75.00 ,the lowest forecast is $75.00. The average price target represents 334.28% Increase from the current price of $17.27.
The highest analyst price target is $75.00 ,the lowest forecast is $75.00. The average price target represents 334.28% Increase from the current price of $17.27.
What do analysts say about Upstream Bio, Inc.?
Upstream Bio, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
How can I buy shares of UPB?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.